A citation-based method for searching scientific literature




Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
Times Cited: 2990




List of shared articles



Times cited

Glucose Lowering Efficacy and Pleiotropic Effects of Sodium-Glucose Cotransporter 2 Inhibitors.
Mohammad Shafi Kuchay, Khalid Jamal Farooqui, Sunil Kumar Mishra, Ambrish Mithal. Adv Exp Med Biol 2021
4

Factors that predict glycaemic response to sodium-glucose linked transporter (SGLT) inhibitors.
Amy L Harding, Naiara Bediaga, Anna Galligan, Peter G Colman, Spiros Fourlanos, John M Wentworth. Intern Med J 2021
0

Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus treated in real-world clinical practice: Results of a 36-month post-marketing surveillance study (J-STEP/LT).
Kazunori Utsunomiya, Ryusuke Koshida, Seigo Kakiuchi, Masayuki Senda, Shoko Fujii, Yuji Kurihara, Ryoji Gunji, Kohei Kaku. J Diabetes Investig 2021
0



Glucagon in type 1 diabetes patients receiving SGLT2 inhibitors: A Friend or Foe?
Tomoyasu Fukui, Makoto Ohara, Sho-Ichi Yamagishi. Diabetes Metab Res Rev 2021
0

SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation.
Katherine R Tuttle, Frank C Brosius, Matthew A Cavender, Paola Fioretto, Kevin J Fowler, Hiddo J L Heerspink, Tom Manley, Darren K McGuire, Mark E Molitch, Amy K Mottl,[...]. Diabetes 2021
3

SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation.
Katherine R Tuttle, Frank C Brosius, Matthew A Cavender, Paola Fioretto, Kevin J Fowler, Hiddo J L Heerspink, Tom Manley, Darren K McGuire, Mark E Molitch, Amy K Mottl,[...]. Am J Kidney Dis 2021
11

Optimizing Management of Type 2 Diabetes and Its Complications in Patients With Heart Failure.
Christie A Schumacher, Elizabeth K Van Dril, Kayce M Shealy, Jennifer D Goldman. Clin Diabetes 2021
0

Identifying Risk Factors for Diabetic Ketoacidosis Associated with SGLT2 Inhibitors: a Nationwide Cohort Study in the USA.
Michael Fralick, Donald A Redelmeier, Elisabetta Patorno, Jessica M Franklin, Fahad Razak, Tara Gomes, Sebastian Schneeweiss. J Gen Intern Med 2021
1





Using adjuvant pharmacotherapy in the treatment of type 1 diabetes.
Åke Sjöholm. Expert Opin Pharmacother 2021
0

Sodium-glucose cotransporter 2 inhibitors: a practical guide for the Dutch cardiologist based on real-world experience.
K Zwart, S Velthuis, Y V Polyukhovych, A Mosterd, L Smidt, E H Serné, D H van Raalte, P J M Elders, M L Handoko, P C Oldenburg-Ligtenberg. Neth Heart J 2021
1

Permission to prescribe: do cardiologists need permission to prescribe diabetes medications that afford cardiovascular benefit?
Abhinav Sharma, Haya Aziz, Subodh Verma, Beth L Abramson, Richard Choi, Grace L Chua, Kim A Connelly, George Honos, G B John Mancini, Sarah A Ramer,[...]. Curr Opin Cardiol 2021
0

Chances and risks of sodium-glucose cotransporter 2 inhibitors in solid organ transplantation: A review of literatures.
Marlene Schwarzenbach, Flavia Elena Bernhard, Cecilia Czerlau, Daniel Sidler. World J Transplant 2021
0

SGLT2 Inhibition by Dapagliflozin Attenuates Diabetic Ketoacidosis in Mice with Type-1 Diabetes.
Huan Chen, Yochai Birnbaum, Regina Ye, Hsiu-Chiung Yang, Mandeep Bajaj, Yumei Ye. Cardiovasc Drugs Ther 2021
0

Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2i) as a Primary Preventative Agent in the Healthy Individual: A Need of a Future Randomised Clinical Trial?
Dan Xu, Owain Chandler, Cleo Wee, Chau Ho, Jacquita S Affandi, Daya Yang, Xinxue Liao, Wei Chen, Yanbing Li, Christopher Reid,[...]. Front Med (Lausanne) 2021
0


Strategically Playing with Fire: SGLT Inhibitors as Possible Adjunct to Closed-Loop Insulin Therapy.
Melissa-Rosina Pasqua, Michael A Tsoukas, Ahmad Haidar. J Diabetes Sci Technol 2021
0

Hormone-substrate changes with exenatide plus dapagliflozin versus each drug alone: The randomized, active-controlled DURATION-8 study.
Ele Ferrannini, Simona Baldi, Juan P Frías, Cristian Guja, Elise Hardy, Enrico Repetto, Serge A Jabbour, Ralph A DeFronzo. Diabetes Obes Metab 2020
2

Beware Ketoacidosis with SGLT2 Inhibitors in Latent Autoimmune Diabetes of the Adult.
Brendan J Nolan, Suresh Varadarajan, Spiros Fourlanos, Sandra L Neoh. Am J Med 2020
2

Diabetic Agents, From Metformin to SGLT2 Inhibitors and GLP1 Receptor Agonists: JACC Focus Seminar.
Tanya Wilcox, Christophe De Block, Arthur Z Schwartzbard, Jonathan D Newman. J Am Coll Cardiol 2020
15


2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: A Report of the American College of Cardiology Solution Set Oversight Committee.
Sandeep R Das, Brendan M Everett, Kim K Birtcher, Jenifer M Brown, James L Januzzi, Rita R Kalyani, Mikhail Kosiborod, Melissa Magwire, Pamela B Morris, Joshua J Neumiller,[...]. J Am Coll Cardiol 2020
58